A Phase 1/2 interventional study of ARU-1801 in Anemia, Sickle Cell, sponsored by Children's Hospital Medical Center, Cincinnati. Terminated at 1 site in United States. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Children's Hospital Medical Center, Cincinnati · Phase 1/2, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Anemia, Sickle Cell by Children's Hospital Medical Center, Cincinnati — 7 open to participants now, 11 under way, none of them phase 3. Anemia, Sickle Cell · Children's Hospital Medical Center, Cincinnati.
Among the 30 studies in Anemia, Sickle Cell by Children's Hospital Medical Center, Cincinnati, this one is the 20th largest by enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2014, is one of 3 in phase 1/2, and was the 11th registered.
1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.
Browse Anemia, Sickle Cell studies →7 of the 30 studies in Anemia, Sickle Cell by Children's Hospital Medical Center, Cincinnati are open now, in 6 countries. Recruiting first, the newest first:
Children's Hospital Medical Center, Cincinnati · Sites in Uganda
Ages 11–18
Children's Hospital Medical Center, Cincinnati · Sites in United States, Ghana, Tanzania
Ages 6 mo–6 yrs
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 13–21
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 6 mo+
Children's Hospital Medical Center, Cincinnati · Sites in Dominican Republic, Jamaica, Tanzania
Ages 8+
By country, each count listing its studies:
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 3 · Phase 4 2
First in 2005; this study’s year is marked. 5 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 40 across 770 interventional studies indexed under Anemia, Sickle Cell.
Median enrollment 66 across the 21 interventional studies, 200 across the 9 observational. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
Children's Hospital Medical Center, Cincinnati is the lead sponsor of 673 studies on the registry; 129 are open to participants now.
Of its 57 completed or terminated interventional studies of FDA-regulated products, 32 (56%) have results posted.
4 of the studies in Anemia, Sickle Cell by Children's Hospital Medical Center, Cincinnati that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07177300Children's Hospital Medical Center, CincinnatiEffectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE) | 2026-12 |
| NCT02286154Children's Hospital Medical Center, CincinnatiTherapeutic Response Evaluation and Adherence Trial (TREAT) | 2026-12 |
| NCT05662098Children's Hospital Medical Center, CincinnatiAlternative Dosing And Prevention of Transfusions (ADAPT) | 2026-12-31 |
| NCT06171217Children's Hospital Medical Center, CincinnatiRealizing Effectiveness Across Continents With Hydroxyurea | 2027-10-04 |
Add all 4 to your calendar (.ics) → With an account.
Among the 30 studies in Anemia, Sickle Cell by Children's Hospital Medical Center, Cincinnati, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this Phase 1/2 study is to determine the feasibility and safety of stem cell collection and gamma-globin gene transfer, and success of gene correction in subjects with sickle cell disease
This study will assess the feasibility, safety and efficacy of gene transfer using ARU-1801 (CD34+ cells transduced with the gamma-globin lentiviral vector). Gene transfer will occur ex-vivo into CD34+ enriched human bone marrow or plerixafor-mobilized peripheral blood hematopoietic stem cells (HSC) collected from subjects with severe sickle cell disease (SCD). Subjects will undergo reduced intensity chemotherapy conditioning with single-dose melphalan to facilitate engraftment of ex-vivo ARU-1801 via IV infusion. Subjects will return to the study site at regular intervals for follow-up for 2 years after the ARU-1801 infusion. It is anticipated that a separate long-term follow-up (LTFU) clinical study will be initiated, in which all subjects completing the 2 year study visit will be asked to consent and enroll, and will followed for a further 13 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has severe sickle cell disease, defined as one or more of the following:
Exclusion Criteria
Other protocol-defined inclusion-exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autologous CD34+ hematopoietic stem cells transduced ex-vivo with gamma-globin lentiviral vector. Administered via IV infusion.
Genetic: ARU-1801
Autologous CD34+ hematopoietic stem cells transduced ex-vivo with a gamma-globin lentiviral vector * Subjects with sickle cell anemia will undergo hematopoietic stem cell procurement by bone marrow harvest or apheresis after mobilization with plerixafor * Reduced intensity chemotherapy conditioning with single dose melphalan will be used to facilitate engraftment of ex-vivo transduced cells.
Number of Participants With Grade 3 Allergic Reaction
Number of Participants with Grade 3 allergic reaction associated with infusion of transduced cell product
Time frame: From infusion (Day 0) to 30 days post-infusion
Number of Participants Grade 4 Infection
Number of Grade 4 infection following infusion of transduced cell product uncontrolled for ≥14 days
Time frame: From infusion (Day 0) to 30 days post-infusion
Total Number of Grade 4 Neutropenia
Number of participants with Grade 4 neutropenia lasting \>1 month following melphalan
Time frame: From date of chemotherapy clearance visit to to 30 days post-infusion
Number of Participants With Grade 3 or 4 Toxicity Events
Number of Participants with Grade 3 or 4 organ toxicity attributable to study procedures
Time frame: From infusion (Day 0) to 30 days post-infusion
Total Number of Adverse Events (AEs) and Serious Adverse Events (SAE)
Time frame: From infusion (Day 0) to 30 days post-infusion
Number of Death Due to Study Procedures
Time frame: From screening to the end of study, and up to 12 months.
Number of Hematological Malignancy
Number of hematological malignancy due to vector insertion
Time frame: From infusion (Day 0) to end of study, up to 12 months
Number of Hematological Cancer
Number of hematological cancer related to investigational product or study medications/procedures
Time frame: From infusion (Day 0) to end of study, up to 12 months.
Time to Neutrophil Recovery
Duration of neutropenia following conditioning (defined as the time from first measurement where absolute neutrophil count (ANC) \< 500 cells/µL to first of 3 consecutive absolute neutrophil count measurements on 3 consecutive days with ANC ≥500 cells/µL)
Time frame: From infusion (Day 0) to end of study, up to 12 months.
Time to Platelet Recovery
Duration of thrombocytopenia following conditioning (defined as the time from first measurement where platelet count \< 50,000 cells/µL to the first of 3 consecutive platelet counts on 3 consecutive days \> 50,000 cells/µL and independent of platelet transfusion for ≥7 days consecutive days)
Time frame: From infusion (Day 0) to end of study, up to 12 months.
≥8x10⁶kg Viable CD34+ Cells
Number of subjects with a total number of CD34+ cells recovered from all collections combined (mobilized peripheral blood and bone marrow) of at least ≥8x10⁶kg viable CD34+ cells
Time frame: Date of Enrollment to Infusion (day 0).
≥4x10⁶ CD34+ Cells/kg Body Weight Transduced
Proportion of subjects for which a minimum of 4x10⁵ CD34+ cells/kg body weight from all collections combined have been successfully transduced
Time frame: Date of Enrollment to Infusion (day 0).
Number of Subjects With Bone Marrow Aspirates With ≥1% Gene-marked Cells
Number of subjects with bone marrow aspirates at 1-year post-infusion with ≥1% gene-marked cells
Time frame: Infusion (Day 0) to 1 year post infusion.
Percentage of HBF^G16D
Percentage of HBF\^G16D relative to total Hemoglobin
Time frame: Infusion to 12 months post-infusion
Change in Proportion of Antisickling/Sickling Hemoglobin
Evaluation of the longitudinal change in the ratio of total antisickling hemoglobin fractions, comprising Fetal Hemoglobin (HbF), the gene-modified hemoglobin variant (HbFG16D), and Hemoglobin A2 (HbA2), relative to Sickling Hemoglobin (HbS). This outcome assesses the stable expression of the therapeutic transgene and the successful shift in the underlying hemoglobin profile post-infusion. Measurements will be performed using Capillary Zone Electrophoresis (CZE) to quantify the individual percentages of each hemoglobin fraction. The antisickling proportion is defined as the sum percentage: (HbF+HbFG16D+HbA2). This value will be compared between the baseline (pre-conditioning/pre-infusion) and the evaluable period through month 24 post-infusion to determine the sustained pancellular distribution of non-sickling hemoglobins. Higher values are considered a successful outcome.
Time frame: Enrollment to Month 24
Percentage of F-retics (Fetal Hemoglobin Content in Reticulocytes)
This measure quantifies the proportion of newly formed red blood cells (reticulocytes) containing detectable levels of fetal hemoglobin (HbF). Because reticulocytes reflect the most recent erythropoietic activity (the last 24-48 hours), this percentage serves as a real-time indicator of the induction of HbF at the erythroid precursor level. This is measured by flow cyctometry.
Time frame: Infusion to 12 months post-infusion
Percent VCN at 6 Months
This measure assesses the percentage of infusion product Vector copy number (VCN) at six months post-infusion in each patient. VCN analysis is performed on DNA from the white blood cell fraction using quantitative polymerase chain reaction (qPCR).
Time frame: Infusion to 6 months post-infusion
Identification and Referral: Potential participants were identified through clinical referral. Hematologists at CCHMC and regional partner institutions referred patients based on primary diagnosis and preliminary eligibility criteria. Setting and Duration: All clinical evaluations, interventions, and follow-up visits were performed at Cincinnati Children's Hospital Medical Center. Accrual Period: The active enrollment and treatment window spanned from July 2014 through October 2022.
| Milestone | Experimental: ARU-1801 |
|---|---|
| Started | 7 |
| Completed | 6 |
| Not completed | 1 |
| Withdrew: Lost to follow-up | 1 |
Number of Participants with Grade 3 allergic reaction associated with infusion of transduced cell product
| Participants | 7 Patients Treated. |
|---|---|
| Number of Participants With Grade 3 Allergic Reaction | 0 |
Number of Grade 4 infection following infusion of transduced cell product uncontrolled for ≥14 days
| Events | 7 Patients Treated. |
|---|---|
| Number of Participants Grade 4 Infection | 0 |
Number of participants with Grade 4 neutropenia lasting \>1 month following melphalan
| Participants | 7 Patients Treated. |
|---|---|
| Total Number of Grade 4 Neutropenia | 0 |
Number of Participants with Grade 3 or 4 organ toxicity attributable to study procedures
| Participants with events | 7 Patients Treated. |
|---|---|
| Number of Participants With Grade 3 or 4 Toxicity Events | 0 |
| Events | 7 Patients Treated. |
|---|---|
| Total Number of Adverse Events (AEs) and Serious Adverse Events (SAE) | 283 |
| Participants | 7 Patients Treated. |
|---|---|
| Number of Death Due to Study Procedures | 0 |
Number of hematological malignancy due to vector insertion
| Participants | 7 Patients Treated. |
|---|---|
| Number of Hematological Malignancy | 0 |
Number of hematological cancer related to investigational product or study medications/procedures
| Participants | 7 Patients Treated. |
|---|---|
| Number of Hematological Cancer | 0 |
Duration of neutropenia following conditioning (defined as the time from first measurement where absolute neutrophil count (ANC) \< 500 cells/µL to first of 3 consecutive absolute neutrophil count measurements on 3 consecutive days with ANC ≥500 cells/µL)
| Days | 7 Patients Treated. |
|---|---|
| Time to Neutrophil Recovery | 8 ± 1 |
Duration of thrombocytopenia following conditioning (defined as the time from first measurement where platelet count \< 50,000 cells/µL to the first of 3 consecutive platelet counts on 3 consecutive days \> 50,000 cells/µL and independent of platelet transfusion for ≥7 days consecutive days)
| Days | 7 Patients Treated. |
|---|---|
| Time to Platelet Recovery | 4.4 ± 2.2 |
Number of subjects with a total number of CD34+ cells recovered from all collections combined (mobilized peripheral blood and bone marrow) of at least ≥8x10⁶kg viable CD34+ cells
| Participants | 7 Patients Treated. |
|---|---|
| ≥8x10⁶kg Viable CD34+ Cells | 5 |
Proportion of subjects for which a minimum of 4x10⁵ CD34+ cells/kg body weight from all collections combined have been successfully transduced
| Participants | 7 Patients Treated. |
|---|---|
| ≥4x10⁶ CD34+ Cells/kg Body Weight Transduced | 6 |
Number of subjects with bone marrow aspirates at 1-year post-infusion with ≥1% gene-marked cells
| Participants | 7 Patients Treated. |
|---|---|
| Number of Subjects With Bone Marrow Aspirates With ≥1% Gene-marked Cells | 7 |
Percentage of HBF\^G16D relative to total Hemoglobin
| Percent | 7 Patients Treated. |
|---|---|
| Percentage of HBF^G16D | 19 ± 0.1 |
Evaluation of the longitudinal change in the ratio of total antisickling hemoglobin fractions, comprising Fetal Hemoglobin (HbF), the gene-modified hemoglobin variant (HbFG16D), and Hemoglobin A2 (HbA2), relative to Sickling Hemoglobin (HbS). This outcome assesses the stable expression of the therapeutic transgene and the successful shift in the underlying hemoglobin profile post-infusion. Measurements will be performed using Capillary Zone Electrophoresis (CZE) to quantify the individual percentages of each hemoglobin fraction. The antisickling proportion is defined as the sum percentage: (HbF+HbFG16D+HbA2). This value will be compared between the baseline (pre-conditioning/pre-infusion) and the evaluable period through month 24 post-infusion to determine the sustained pancellular distribution of non-sickling hemoglobins. Higher values are considered a successful outcome.
| Percent antisickling/sickling hemoglobin | 7 Patients Treated. |
|---|---|
| Change in Proportion of Antisickling/Sickling Hemoglobin | 19.2 ± 7.8 |
This measure quantifies the proportion of newly formed red blood cells (reticulocytes) containing detectable levels of fetal hemoglobin (HbF). Because reticulocytes reflect the most recent erythropoietic activity (the last 24-48 hours), this percentage serves as a real-time indicator of the induction of HbF at the erythroid precursor level. This is measured by flow cyctometry.
| Percent | 7 Patients Treated. |
|---|---|
| Percentage of F-retics (Fetal Hemoglobin Content in Reticulocytes) | 68 ± 20 |
This measure assesses the percentage of infusion product Vector copy number (VCN) at six months post-infusion in each patient. VCN analysis is performed on DNA from the white blood cell fraction using quantitative polymerase chain reaction (qPCR).
| Percent | 7 Patients Treated. |
|---|---|
| Percent VCN at 6 Months | 36 ± 20 |
Collected over Adverse events enrollment through 30 days post infusion. All cause mortality screening to end of the study, up to 12 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 7 Patients Treated. | 0/7 (0%) | 3/7 (42.9%) | 7/7 (100%) |
| Event | 7 Patients Treated. |
|---|---|
| Vaso-occlusive painful crisisBlood and lymphatic system disorders | 3/7 |
| Event | 7 Patients Treated. |
|---|---|
| Sickle Cell CrisisBlood and lymphatic system disorders | 7/7 |
| PainGeneral disorders and administration site conditions | 7/7 |
| InfectionInfections and infestations | 7/7 |
| Decreased LymphocytesInvestigations | 7/7 |
| Decreased PlateletsInvestigations | 7/7 |
| HeadacheNervous system disorders | 7/7 |
| Decreased Abs NeutrophilInvestigations | 6/7 |
| PyrexiaGeneral disorders and administration site conditions | 5/7 |
| AlopeciaSkin and Subcutaneous Tissue disorders | 5/7 |
| DiarrhoeaGastrointestinal disorders | 4/7 |
The analysis population includes all seven (7) enrolled participants with a confirmed diagnosis of severe sickle cell disease who underwent successful mobilization and apheresis, received myeloablative conditioning, and were administered one intravenous infusion of autologous CD34+ cells transduced with the Gamma Globin Lentivirus Vector.
| Age, Categorical(Participants) | ARU-1801 |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 7 |
| >=65 years | 0 |
| Age, Continuous(Years) | ARU-1801 |
|---|---|
| Mean | 22 (19 to 34) |
| Sex: Female, Male(Participants) | ARU-1801 |
|---|---|
| Female | 6 |
| Male | 1 |
| Race (NIH/OMB)(Participants) | ARU-1801 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 7 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | ARU-1801 |
|---|---|
| United States | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2014 to primary completion in Oct 2022, 99 months.
Results were first posted in Nov 2026, 4 years after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Children's Hospital Medical Center, Cincinnati →